Sentences with phrase «price of the shares over»

While DCA does result in your average cost per share being lower than the average price of the shares over time, in a bear market you can still suffer temporary setbacks.

Not exact matches

Combine that with a sparkling balance sheet and its history of never cutting its dividend — the yield is now 2.5 % — and its beaten - down share price (down by a third over the past two years) looks like an opportunity to pick up a high - quality bargain.

One of the outcomes of the much ballyhooed housing summit earlier this week between Sousa, his federal counterpart Bill Morneau and Toronto mayor John Tory was a commitment to «sharing relevant data more regularly between governments to enhance understanding,» a move that seems comically late after prices in the region have surged double - digits over the past few months.

The price of Lucara shares has been on a tear ever since, popping 150 % over the past six months.

The share prices of big entertainment companies have been extremely volatile over the past year as investors try to assess the winners and losers in the changing video ecosystem.

Specifically, Defendants made false and / or misleading statements and / or failed to disclose that: (i) Akorn's failure to comply with FDA data integrity requirements would jeopardize Fresenius» acquisition of Akorn; (ii) the Company lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, Akorn shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

In 2013, for example, Magnetar and several other hedge funds sued over the acquisition by 3M (mmm) of biometrics company Cogent, seeking about 55 % more money for their shares in the target, which they claimed were priced too low.

The company said in February that it planned to buy back up to $ 5 billion of stock over 2018 - 2020 to share the benefits of higher oil prices with investors.

Apple's stock dipped at the start of 2016 due to concerns over a slowdown in iPhone sales, though share prices have since rebounded into positive territory for the year amid investor optimism for the company's new line of products.

Over the past two years, Groupon's stock price has gone from $ 26 a share on its first day of trading in November 2011 to less than $ 3 a share a year later.

Over most of that period, producers alternated losses with profits, their capital allocation was suspect and share prices barely budged.

Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx, a premium of 21.2 percent over its closing price on Friday - and more than double the price before Novo went public with its initial offer.

NEW YORK, April 13 - Oil prices extended recent gains and a gauge of global stocks eased on Friday as concern over a broader conflict in Syria left investors nervous, while U.S. bank shares led Wall Street lower.

However analysts point to a bounce in Teva's shares over the past four months and a slowing in the rate of decline of U.S. generic drug prices as bright spots.

Shareholders approved the sale, which paid them $ 13.65 in cash for each share of common stock, a 37 % premium over the recent average closing price.

Exploration firm Red River Resources has seen its share price jump by over 80 per cent after it entered into a $ 6.5 million agreement with the administrators of collapsed explorer Kagara, for the sale of its projects in northern Queensland.

When you purchase a broad swath of equities, say an S&P 500 index fund, the returns you can expect over the next decade or so comprise four building blocks: the starting dividend yield, projected growth in real earnings per share, expected inflation, and the expected change in «valuation» — that is, the expansion or contraction in the price / earnings (P / E) multiple.

Over the past five of years, CCL's share price has shot up nearly 600 %.

Nokia will pay 0.55 share for every share of Alcatel - Lucent, offering shareholders a premium of around 28 percent to the weighted average share price over the past three months, Nokia said.

Under the Osmere deal, Infobank will take up to 43 million shares at a price of 40 cents per share — representing a 33.3 per cent premium over the 30 cent issue price of a $ 7.5 million placement and rights issue announced during February.

The exact share exchange ratio will be determined by looking at the volume - weighted average stock price of the companies over the last few months, one of the sources added.

Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx, a premium of 21.2 % over its closing price on Friday — and more than double the price before Novo went public with its initial offer.

It's down about 14 % to $ 2.45 on Thursday at the time of publishing, a far cry from the company's stock price of over $ 14 per share in 2012.

While still shy of the initial $ 38 share price at its IPO over one year ago, investors finally have reason to feel good about its prospects.

If Netflix sees high revenue increases over the next couple of years, based on strong subscriber growth, customer retention, and low marketing spend, he predicts the share price could reach $ 480.

Market share had grown from 14 percent to 21 percent, and the stock price was over $ 40 (it is holding at $ 78 as of this writing).

It seems that Netflix investors might be coming down from their cloud of «euphoria» (as CEO Reed Hastings put it) over the company's share price.

From Thursday's close of $ 17.49, shares would need to climb more than 14 percent to hit the 20 strike price over the next month.

Microsoft Corp., which is in Redmond, Washington, is paying $ 196 for each share of LinkedIn Corp., a 50 per cent premium over the stock's closing price of $ 131.08 on Friday.

In preparation for testimony before the House of Commons finance committee in Ottawa on March 10, I pulled together some thoughts on three aspects of the impact of the oil - price crash on oil sands projects and policies, and I thought I'd share them with you here over this and the next couple of posts.

After a healthy run earlier this year, shares of Salesforce took a hit in June, falling 8 percent before finding a floor of support at the stock's 50 - day moving average, a technical indicator that smooths out a stock's random price fluctuations over a given time.

On Thursday, the shares were dropping again, down 6 % and back around the original IPO price, thanks to growing resentment over an ugly redesign of Snap's app.

Louisiana - Pacific said it will pay C$ 3.76 per share for all of the remaining common shares in the Canadian lumber company, resulting in an approximate 30 per cent premium over the company's closing price of C$ 2.89 on Sept. 3.

«I think there's a lot of focus upon the top line in the bank and over near - term we have been fairly flat on the top line, but if you look back over the last nine months, actually the top line is up about 5 percent,» Halford said about the share price move.

In what might represent the concerns over Proton, Citi, for one, noted that the deal would improve the valuation of the seller, raising its target price for DRB - Hicom's shares to 2.30 ringgit from 1.86 ringgit, keeping a Buy / High Risk call on the stock.

Nintendo shares tumbled 5.75 percent to 23,750 yen at the close of trade, and commentators said the higher than expected retail price of the console fanned concerns over the product's viability.

For that reason, Northrop shares edged up only 0.3 % in early trading Monday, suggesting that, while the deal made lots of sense over the long term, the price is pretty full and the buyer has less practice than some at integrating new businesses, especially big ones.

Wells Fargo downgraded the company to market underperform, and put a price target of $ 7 a share on it, over a buck above its current price — always lagging behind, always keeping that optimism going.

Lastly, the price paid by Northrop — $ 134.50 a share — is some 22 % above Orbital's closing price Friday, and Orbital had already risen over 20 % this year, thanks to expectations of a windfall from the Trump administration's pledge to overhaul the strategic arsenal.

Apollo said it will pay $ 17.12 per share in cash for ClubCorp, a 30.7 percent premium over its closing price on Friday, but less than the 12 - month high of $ 17.50 the shares reached in February, on investor expectations that a sale process first reported by Reuters in January would be successful.

A test for the shares looms on Wednesday, when Mylan CEO Heather Bresch testifies before the U.S. House of Representatives Oversight Committee over price increases of EpiPen, an auto - injector of allergy medicine.

Redstone and daughter Shari have been trying to get rid of Dauman for months, arguing that he has failed to build value at the company and has presided over a huge drop in the share price (VIAB).

Instead, if the investor is purchasing $ 5,000 worth of stock at a warrant - conversion price of $ 2,000, the company subtracts the cost of the conversion and actually turns over only $ 3,000 worth of shares to its investor.

Shares of Mylan (myl) are trading at historically low valuations as the company's chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatment.

That may explain why Japan's Suntory jumped ahead of a number of European suitors, including France's Pernod Ricard, to bid for Beam last month — offering to pay Beam stockholders $ 83.50 per share, a 25 % premium over the stock's then - market price of around $ 67, in addition to assuming some $ 2.4 billion in company debt.

But interest from the underwriters was such that the same shares were offered instead at $ 18 — and doubled in price over their first two weeks of trading.

The purchase gave another boost to the company's share price, which had already gone from $ 40 to over $ 60 in 2014, with a full year total stockholder return of 64 %.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

If the participant sells the ISO shares prior to the expiration of these holding periods, the participant recognizes ordinary income at the time of disposition equal to the excess if any, of the lesser of (1) the aggregate fair market value of the ISO shares at the date of exercise and (2) the amount received for the ISO shares, over the aggregate exercise price previously paid by the participant.

The company's share price has climbed steadily over the course of the year, a trend lofted by expectations of increased defense spending under the new administration as well as strong demand for its Pratt & Whitney jet engines and other aerospace parts.